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Studies suggest that estrogen therapy (ET) and combined estrogen-progestogen therapy (EPT) may have different associations
with colorectal cancer (CRC) risk, but data are conflicting. Prior meta-analyses did not distinguish between ET and EPT. We
conducted a meta-analysis to summarize the relative risks (RR) of CRC due to ET versus EPT among peri- or postmenopausal
women. From a total of 2,661 articles, four randomized controlled trials, eight cohort and eight case-control studies were
included. Variables assessed included study characteristics, duration and recency of menopausal hormone therapy (HT) use,
method of assessment of HT use, outcome definition and its ascertainment method. RRs were synthesized by random-effects
models. We found that EPT ever use was associated with a decreased risk of CRC (RR 0.74, 95% CI 0.68-0.81), and so was ET
ever use (RR 0.79, 95% CI 0.69-0.91). While current use of ET was associated with a significantly reduced risk of CRC (RR
0.70, 95% CI 0.57-0.85), former use was not (RR 0.86, 95%CI 0.67-1.11). Recency did not significantly modify the association
between EPT and CRC risk. EPT former use was associated with a lower RR of CRC compared to ET former use (p 5 0.008) but
no such difference was observed between EPT and ET current use (p 5 0.12). Overall, we found consistent evidence
supporting the association between EPT and CRC risk reduction, regardless of recency. While literature for the association
between ET and CRC risk is heterogeneous, our analyses suggest only current use of ET is associated with a decreased
CRC risk.
Menopausal hormone therapy (HT) is indicated for short-
term control of intolerable menopausal symptoms and it has
a limited role in the treatment of osteoporosis for selected
woman. While HT was found to increase the risks of venous
thromboembolism, breast cancer and stroke, studies have
also suggested that it may be associated with a reduced risk
of colorectal cancer (CRC).1 Grodstein et al. conducted a
meta-analysis of 18 observational studies that summarized
the effect of HT on CRC risk, and showed an overall inverse
association, with a pooled relative risk (RR) of 0.80 (95% CI
0.74-0.86).2 Another meta-analysis published by Nanda et al.
revealed similar results.3 The explanation for the observed
association has been controversial, however, because selective
prescribing of HT to healthier subjects (i.e., healthy user
bias) may have accounted for superior outcomes in the HT
group. This concern was partly settled by the Women’s
Health Initiative (WHI) study, a large-scale randomized con-
trolled trial (RCT), which found that the use of conjugated
equine estrogens plus medroxyprogesterone acetate was asso-
ciated with a reduction in CRC risk.4 In contrast, one study
did not ﬁnd a signiﬁcant association between the use of con-
jugated equine estrogen alone and CRC risk, although the
small number of CRC cases may have limited its interpreta-
tion and generalizability.5 In fact, the WHI study results were
not directly comparable with previous observational studies
and meta-analyses since the majority of these had investi-
gated HT overall without differentiating between estrogen
therapy (ET) vs. combined estrogen-progestogen therapy
(EPT; progestogen encompasses both progesterone and pro-
gestin6). Therefore, we conducted a meta-analysis to summa-
rize the available evidence and to compare the RR of CRC
due to ET vs. EPT among peri- or postmenopausal women.
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Material and Methods
Study selection
We searched PubMed and EMBASE for studies conducted
up until September 2010 that investigated the association
between ET or EPT and CRC risk among peri- or postmeno-
pausal women. Articles were identiﬁed using the following
key words: estrogen, hormone replacement therapy, meno-
pausal hormone therapy, estradiol congeners, progestogen,
progesterone and progestins in conjunction with colorectal
neoplasm, such as colorectal, colon, sigmoid, or rectal cancer,
tumor, or carcinoma. All of the above terms were entered as
both MESH (exploded in EMBASE) terms and text words.
The search was restricted to human studies. We did not
consider estimates published solely in the form of letters,
commentaries, or abstracts. Case reports, reviews, or meta-
analyses were also excluded. All entries retrieved by this strat-
egy, plus references of eligible articles and key reviews, related
to the effect of HT on CRC risk were examined to identify
studies that satisﬁed the following predeﬁned inclusion crite-
ria: (i) Studies must have evaluated peri- or post-menopausal
women. Studies investigating the association between oral
contraceptives and CRC risk in young women were excluded;
(ii) The primary exposure of interest was either ET or EPT.
We did not consider those with nonspeciﬁc or mixed HT;
(iii) Study endpoints were CRC, colon, or rectal cancer; and
(iv) Studies were required to have reported or provided sufﬁ-
cient data to calculate the RR and derive its standard error.
Data extraction
Two independent investigators (KJL, JYCL) extracted the
data from eligible articles, and a third investigator (WYC)
validated the collected data for accuracy. If available, we
extracted RRs, including ratios of cumulative incidence, inci-
dence rates, and odds of developing the outcomes of interest,
which were reported in the original articles. Information on
study methods and quality-related characteristics were also
documented. Variables that were evaluated included: year of
publication and year of study, geographic region, inclusion
and exclusion criteria of the study population, sample size,
mean age of the study population, prospective vs. retrospec-
tive design, HT type, deﬁnitions for current vs. ever vs. never
use, duration and recency of HT use, and duration of follow-
up. Also, all articles were assessed for potential biases, includ-
ing confounding, selection and information bias. For con-
founding bias, we extracted all the variables adjusted in each
study and categorized the adjustment into: (i) no multivariate
adjustment; (ii) with multivariate adjustment, including con-
trolling for screening procedures, such as colonoscopy and
sigmoidoscopy; (iii) with multivariate adjustment which did
not include screening procedures. For selection bias, we
extracted the participation rate if a study was questionnaire/
interview-based and evaluated the characteristics among
respondents and nonrespondents. Also, suboptimal (less than
70%) or differential participation rate among cases vs. con-
trols, or signiﬁcant loss to follow up (>10%) was considered
a potential source of selection bias. For information bias, we
evaluated each study for its methods of assessing HT expo-
sure status and ascertaining cases of CRC. The methods of
HT exposure assessment used by the selected studies can be
categorized into three groups: (i) objective documents, such
as medical charts, claims databases, or pharmacy records; (ii)
HT allocation in a RCT; and (iii) patient self-report, such as
interviews or questionnaires. The methods of case ascertain-
ment used by the selected studies can be categorized into two
groups: (i) cases ascertained by a cancer registry; (ii) cases
identiﬁed by review of medical records. Of note, none of the
included article ascertained cases by self-report methods (i.e.,
questionnaire/interviews) alone.
Statistical analyses
All RRs extracted were the most ﬁnely adjusted estimates
from the original studies. If one study presented estimates for
multiple HT types (e.g., ET and EPT) or multiple disease def-
initions (e.g., CRC, colon cancer and rectal cancer), all of
them were considered. If RRs were reported for different
durations and recency of HT use, all of them were included
since duration and recency were variables of interest. If RRs
for the same population were reported more than once but
in different articles, only the RRs from the most recent study
were included.
Random effects models were applied to calculate pooled
RRs and their 95% conﬁdence intervals (CIs). In terms of HT
exposure status, all included studies used ‘‘never use’’ as the
referent group; and most studies used ‘‘ever use’’ as the pri-
mary exposure group. For studies reporting estimates regard-
ing recency of use, ever HT use was subdivided into current vs.
former use, as assigned by individual studies. For studies
reporting estimates regarding duration of use, ever HT use was
subdivided into short-term vs.. long-term use. To avoid ambi-
guity of intermediate duration, if a study reports estimates for
duration of more than two categories, only the estimates for
the shortest and longest duration were included in the analysis.
For instance, if a study reports estimates for HT exposure with
duration <5, 5–10 and >10 years, the estimate for <5 years is
considered short-term use and the estimate for >10 years is
long-term. Among the studies included in our analysis, 5 years
is the most common cut-off used to deﬁne short-term vs. long-
term use. Heterogeneity of effect estimates was assessed by the
Cochrane Q test for heterogeneity7 and the I2 statistic
described by Higgins and Thompson, which quantiﬁes the pro-
portion of total variability attributable to between-study varia-
tion.8 To further determine study characteristics and their
inﬂuence on RR estimates, we performed meta-regressions
where we regressed the study-speciﬁc log-transformed RRs by
the study characteristics variables, weighting the studies by the
inverse of the sum of within-study and between-study var-
iance.9 Since data from different studies are only combinable
when the study populations are homogenous, we performed
subgroup analysis, pooling studies within the same category of
the variables that are signiﬁcant factors in the meta-regression
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models. If any of the RRs in the meta-regression model were
extracted from the same studies for different HT types or mul-
tiple outcome deﬁnitions, we would use a generalized linear
model to account for the correlation between observations. We
explored potential publication bias using both Begg’s and
Egger’s test.10,11 Stata 10.1 (Stata Corp., College Station, TX)
was used for pooling the RRs and SAS 9.2 (SAS Institute Inc.,
Cary, NC) was used for meta-regression models. All reported
p-values were based on two-sided tests with a signiﬁcant level
of 0.05.
Results
We identiﬁed 1259 relevant titles from Pubmed and 1913
from EMBASE. We discarded 511 duplicates that were iden-
tiﬁed by both databases. We rejected 1036 because they were
not original articles and 1284 because they were either in
vitro studies or those evaluating populations other than peri-
or post-menopausal women. Of the remaining articles, we
excluded 120 because CRC was not an outcome; 163 because
HT was not an exposure; 25 because no speciﬁc HT type was
speciﬁed; 5 because they used a repeated population, 5
because they investigated effects only among cancer patients;
1 because it used extrapolated RR to calculate risk difference,
1 because it was a cross-sectional study and used prevalent
instead of incident cases.12 Review of references among eligi-
ble studies and key reviews identiﬁed one additional article.13
One study investigated the association between tibolone and
CRC risk.14 Because tibolone has androgenic effect in addi-
tion to estrogenenic and progestogenic effect and is different
from conventional HT regimens, we only included it in an
exploratory analysis and treated tibolone as one kind of EPT.
Another study only differentiated ET from EPT in an univar-
iate analysis,15 so we excluded it in our primary analysis. Of
note, including it in an exploratory analysis did not materi-
ally change our results. Therefore, 20 articles were included
in our primary analysis (Fig. 1).4,5,13,16–32 Table 1 summarizes
their characteristics.
Figure 1. Flow chart of literature search for studies on the association between speciﬁc menopausal hormone therapy and colorectal
cancer; CRC: colorectal cancer; RCT: randomized controlled trial; HT: menopausal hormone therapy.
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Figure 2 shows the RR estimates reported by individual
studies as well as the random effects pooled estimates for
both ET and EPT. The pooled RRs of CRC were 0.79 (0.69-
0.91) for ET ever use and 0.74 (0.68-0.81) for EPT ever use.
Among former users, EPT was associated with a signiﬁcantly
lower RR of CRC compared to ET (p ¼ 0.008); in contrast,
among current users, the RR was not signiﬁcantly different
for ET vs. EPT (p ¼ 0.12). When pooled together, there was
no apparent difference in the overall estimate for ET and
EPT ever use (p ¼ 0.43, Table 2). Substantial heterogeneity
was found among studies reporting RRs for ET (Cochrane Q
test: p < 0.001). Test for heterogeneity among EPT studies
were not signiﬁcant (Cochrane Q test p ¼ 0.88).
Table 2 shows the results from the stratiﬁed analyses. For
ET studies, the inverse association was more prominent in
case-control studies than in RCTs and cohort studies. The
pooled RRs of CRC for ET studies were 0.65 (0.51-0.82)
from case-control studies, 0.89 (0.75-1.04) from cohort stud-
ies, and 1.08 (0.75-1.55) from the RCT. This difference was
signiﬁcant in the meta-regression model where case-control
studies gave a signiﬁcantly smaller RR than cohort studies (p
¼ 0.018) and RCTs (p ¼ 0.0023). On the other hand, EPT
studies reported similar RRs regardless of study design. In
both ET and EPT studies, there was a trend that pooled esti-
mates for colon cancer were lower than those for rectal can-
cer. The pooled RR associated with ET ever use was 0.74
(0.61-0.89) for colon cancer, 0.86 (0.75-0.99) for rectal cancer
and 0.84 (0.73-0.97) for CRC. Similarly, the RR associated
with EPT ever use was 0.78 (0.69-0.89) for colon cancer, 0.87
(0.70-1.08) for rectal cancer and 0.74 (0.66-0.82) for CRC.
There was no apparent difference in pooled RRs of CRC
for either ET or EPT use of different duration. For recency
of HT use, however, differences in the risks of CRC were evi-
dent among ET vs. EPT users. In the ET group, the RR of
CRC associated with current use was 0.70 (0.57-0.85), which
was signiﬁcantly lower than that associated with former use
(RR 0.86, 0.67-1.11; p-value for difference between current
and former use <0.0001). For EPT, however, there was no
signiﬁcant difference between current use and former use
(p ¼ 0.25).
Figure 3 shows funnel plots by HT types. There was no
evidence of publication bias for either group. For ET, the p-
value of Egger’s test was 0.48 and Begg’s test was 0.41. For
EPT, the p-value of Egger’s test was 0.65 and Begg’s test was
0.54.
We examined the included studies for potential informa-
tion, selection and confounding bias. We found misclassiﬁca-
tion of the outcome unlikely in all included studies since all
of the cancer cases were identiﬁed through either registries or
chart review which usually requires veriﬁcation with pathol-
ogy reports. As for misclassiﬁcation of HT status, we found
that ET studies where HT exposure was assessed by self-
report showed a pooled RR of 0.68 (0.57-0.81), which was
signiﬁcantly lower than that obtained by objective methods
with a pooled RR of 0.99 (0.84-1.16, p-value for theTa
b
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difference <0.0001). However, this difference was not
observed among EPT studies. In our meta-regression models,
we did not ﬁnd signiﬁcant differences in studies with vs.
without other quality-related characteristics, including multi-
variate adjustment (p ¼ 0.74 for ET and 0.53 for EPT stud-
ies), adjustment for screening procedures (p ¼ 0.10 for ET
and 0.30 for EPT studies) and potential for selection bias (p
¼ 0.28 for ET and 0.26 for EPT studies).
Sensitivity analysis was done by omitting one study at a
time to evaluate the inﬂuence of individual studies. Figure 4
demonstrates how the pooled estimate changed when a cer-
tain study was omitted. Overall, no single study was identi-
ﬁed as extremely inﬂuential for either HT type. For ET, omit-
ting the most inﬂuential study by Wu et al. resulted in a
pooled RR of 0.82 which was close to the overall pooled esti-
mate of 0.79 and within its 95% CI of 0.69-0.91. No single
inﬂuential study was identiﬁed among EPT studies.
Discussion
Based on our meta-analysis, there is consistent evidence sup-
porting the association between EPT and CRC risk reduction.
However, we found signiﬁcant heterogeneity among the ET
studies. Several factors were identiﬁed as potential explana-
tion for this heterogeneity, including: recency of HT use,
study design, and method of HT exposure assessment.
The WHI study showed a signiﬁcant inverse association
with CRC risk for EPT, but not for ET. While our results for
EPT are consistent with WHI ﬁndings, we found that current
use of ET was also associated with a reduced risk of CRC.
This difference may be explained by the low adherence rates
in the ET arm of the WHI: 53.8% of women had stopped
taking the study medication by the end the study. Nondiffer-
ential misclassiﬁcation of the exposure could bias the results
towards the null. Furthermore, women assigned to receive ET
who dropped out early during follow-up may very well repre-
sent former rather than current users of ET, which is consist-
ent with our analysis showing a lack of association between
former use and CRC risk. Grodstein et al. conducted a meta-
analysis summarizing the effect of HT on CRC risk from 18
observational studies and showed an overall inverse associa-
tion, with a pooled RR of 0.80 (0.74-0.86).2 In the current
study, 13 articles have provided estimates for both ET and
EPT use. By combining the two arms, we found the pooled
RR of CRC associated with mixed HT ever use to be 0.81
(95% CI 0.74-0.89), which is very similar to the results from
the prior study. Another meta-analysis published by Nanda
et al. found that this association was limited to recent use
(RR 0.67, 0.59-0.77); ever use of HT was not signiﬁcantly
associated with colon cancer risk reduction (RR 0.92, 0.79-
1.08).3 Since the majority of the articles included in these
two prior meta-analyses did not differentiate between ET and
EPT use, their pooled estimates cannot be directly compared
with our results.
In our analysis, recency played an important role for the
association between ET and CRC risk. Speciﬁcally, current
users of ET, but not former users, had a signiﬁcant CRC risk
reduction. For EPT users, however, both current and former
users had a signiﬁcant reduction in CRC risk. As a result,
EPT was associated with a signiﬁcantly lower RR of CRC
than that conferred by ET (p ¼ 0.008) among former users,
but not among current users (p ¼ 0.12). When pooled to-
gether, there was no apparent difference in the overall esti-
mate for ET and EPT use (p ¼ 0.43).This ﬁnding suggests
that the inclusion of progestogen in HT not only strengthens
its effect against CRC, but makes this effect persist despite
discontinuing the medication. On the other hand, duration of
use did not appear to modify CRC risk in either ET or EPT
signiﬁcantly. The fact that even short-term use reduced CRC
Figure 2. Forest plots by menopausal hormone therapy types; on the left are the ﬁrst author and the publication year of the study reporting
the estimate. [Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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risk suggests that estrogens may intervene on carcinogenesis
in the late stages of disease by effectively halting tumor pro-
gression. The immediacy of this effect makes it biologically
implausible for HT to have acted on tumor formation, since
a time lag between exposure and effect would be expected in
this setting.
ET was associated with lower CRC risk in case-control stud-
ies only. This ﬁnding based on study design was not observed
in the EPT group. It is important to note that case-control
studies included more CRC cases than in RCTs and cohort
studies. Among the selected articles in the current meta-analy-
sis, the mean total number of cases was 89 (standard error
[s.e.] 6-166) for RCTs, 361 (s.e. 229-493) for cohort and 969
(s.e. 496-1442) for case-control studies. Because CRC is a rela-
tively rare disease, smaller studies may not be sufﬁciently pow-
ered to detect the full effect of HT. However, this factor can
only explain the difference in the degree of signiﬁcance, but not
in the magnitude of association.
Another potential explanation for a signiﬁcant association
only in case-control studies is the method of HT exposure
assessment. When compared to other study designs, case-
control studies were more likely to use self-report to identify
Figure 3. Funnel plots by menopausal hormone therapy types.
Figure 4. Sensitivity analysis.
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HT exposure status (Fisher’s exact p ¼ 0.009). Self-report is
subject to recall inaccuracies whereby former users are likely
to recall their use incorrectly. Csizmadi et al. compared self-
reported data with objective dispensing data for a subsample
of women and found former users tended to forget their HT
use and thus be misclassiﬁed as nonusers.27 As a result, the
investigators of case-control studies might be ascertaining
current or recent users despite that they attempted to identify
ever users (encompassing both current/recent and former
users). Indeed, the signiﬁcant association between ‘‘ever use’’
of ET and CRC risk observed in case-control studies was
similar to that for current use of ET regardless of study
design. In a subanalysis, we also found that, even among
case-control studies, HT assessment by self-report showed a
lower pooled RR of 0.59 (95% CI 0.44-0.80) when compared
to that using other methods (RR 0.85, 0.76-0.95). Taken to-
gether, it is likely that only current use of ET was associated
with a CRC risk reduction and case-control studies tended to
ﬁnd this speciﬁc association if the HT exposure was assessed
by self-report. Incorporating former use, studies of other
designs found mostly nonsigniﬁcant association between ever
use of ET and CRC risk. Interestingly, recency appeared to
play a less important role for the effect of EPT on CRC risk.
Therefore, case-control design and HT assessment by self-
report did not make a signiﬁcant difference in the association
between EPT and CRC risk.
It is also possible that the stronger association between ET
use and CRC risk in studies using self-report HT status may
be due to misclassiﬁcation of EPT as ET use, assuming EPT
was associated with a lower RR compared to that of ET. If
this were the case, we would expect that EPT studies using
self-report to ﬁnd a weaker association between EPT use and
CRC risk (due to mixing of EPT and ET, the latter which
has a weaker association with CRC risk). We did not observe
this pattern (RR was 0.74 vs. 0.76 in self-report vs. non-self-
report EPT studies). Moreover, current use of ET was associ-
ated with a lower RR compared to former use in our analysis.
Theoretically, the possibility that women incorrectly reported
using ET when they actually used EPT is higher in former
than in current users. Consequently, we should have observed
stronger association between CRC risk and ET former use
compared to that with ET current use, which is not apparent
in our ﬁndings.
Our results are consistent with the WHI33 and prior
meta-analysis3 that HT is associated with a lower risk of
CRC or colon cancer, but less so with rectal cancer. This
trend was observed for both ET and EPT studies. One possi-
ble explanation is that colon and rectal cancers behave differ-
ently. First, there is strong evidence supporting the histologi-
cal differences between the two diseases. Second, the
anatomical location of rectal tumors allows for more rapid
progression of disease. As it is not surrounded by perito-
neum, neoplasms in the rectum encounter fewer barriers for
spread and growth. If the effect of HT actually comes from
its effect on the late stages of carcinogenesis, the aggressive-
ness of rectal cancer leaves less opportunity for HT to inter-
vene on cancer development.
Several mechanisms have been postulated to explain the
effect of HT on CRC risk. One theory involves carcinogenic
bile acid of which the synthesis is reduced for woman on
ET.34–36 Based on in vitro studies, others postulate that estro-
gen may have a direct effect on steroid hormone receptors
found in colonic epithelium. Activation of the receptors can
pose a downstream effect that likely leads to inhibition of cell
growth.37–39 Furthermore, some prior research suggests that
estrogen itself is tumor suppressive and HT may enhance
this relationship. For instance, methylation of the promotor
region of estrogen receptor gene has been linked to human
colon cancer.40 There is also evidence to indicate that use of
estrogen can reduce the serum insulin-like growth factor-1
(IGF-1) levels for postmenopausal women.41,42 Increased en-
dogenous IGF-1 secretion has been linked with higher risk of
CRC.43,44 Estrogen may also be tumor suppressive by induc-
ing apoptosis in premalignant cells caused by p53 and p21
protein expression.45 Moreover, progestogen could accelerate
the conversion of the less potent estrone to the more potent
estradiol by inducing the key enzyme, isozyme of 17h-
hydroxy steroid dehydrogenase.46,47
Although our results support the association between EPT
and CRC risk reduction, some have raised doubts about this
association. It is observed that only early-stage colon cancers
were reduced by EPT in WHI,33 and the risk reduction for
colon cancer of both early and advanced stage was not
observed in the postintervention phase. Since WHI was a
large-scale RCT, it is unlikely that the observed association
was due to confounding. An alternative explanation is that
EPT delays the diagnosis of early-stage colon cancer through
a biologic effect (e.g., decrease in tumor bleeding).33,48 While
results from WHI postinterventional phase did not show any
mortality beneﬁt from the lower incidence rate among EPT
users compared to nonusers, this is compatible with the ex-
planation of delayed diagnosis caused by EPT or simply the
inadequate length of follow-up to reveal any demonstrable
mortality beneﬁt.48 In contrast, Newcomb et al. found that
EPT was associated with a risk reduction not only for local-
ized, but also for advanced CRC.17 We believe further studies
on the association between speciﬁc stages of CRC and ET vs.
EPT as well as on the potential biologic mechanism for the
effect of EPT on delaying CRC diagnosis are needed to con-
ﬁrm the causal relationship.
In an exploratory analysis, we included an RCT investigat-
ing the association between tibolone and CRC risk.14 Tibo-
lone is approved in 90 countries to treat menopausal symp-
toms and its metabolites have estrogenic, progestogenic and
androgenic activities.49,50 Adding our study to the EPT group
yielded a pooled RR of CRC 0.74 (0.68-0.81), which is essen-
tially unchanged compared to our primary analysis. However,
the magnitude in risk reduction of colon cancer associated
with tibolone use reported by this additional study (RR 0.31,
0.10-0.96) was greater than conventional EPT (pooled RR of
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colon cancer: 0.80, 0.65-0.99). This difference can be
explained by different biologic effects of tibolone vs. conven-
tional EPT; or simply by chance since this comparison was
based on only one study for tibolone with 17 colon cancer
cases.
We need to acknowledge several limitations. For meta-
analyses to combine and integrate results of independent
studies together, the studies should be similar and compara-
ble. However, this can be a strong assumption when dealing
with a pool of RCTs and observational studies that are based
on different populations, different diseases and different
methods of exposure and outcome assessment. Indeed,
among ET studies, we observed signiﬁcant heterogeneity,
mainly by study design. Further stratiﬁcation of the analysis
according to some of the study characteristics provided more
homogeneous subgroups, but some subgroup analyses were
based on relatively few studies (e.g., the analyses for duration
and recency of HT) and thus the results should be inter-
preted with caution. In addition, despite our attempt for a
thorough search, it is possible that eligible articles may have
been missed. This may reduce the power of our study and
lead to a more conservative pooled estimate and it may also
result in biased pooled estimates if we selectively missed
studies reporting extreme estimates. To avoid this bias, the
decisions regarding inclusion or exclusion of a study had
been made independently of their results. It is reassuring that
our sensitivity analysis did not identify any inﬂuential studies.
In addition, our meta-analysis involves 16 observational stud-
ies that are vulnerable to confounding. Nonetheless, the
‘‘multivariate adjustment for confounding’’ was not a signiﬁ-
cant factor affecting RR estimates in the meta-regression
model. Furthermore, because of the small number of selected
studies in our analysis, we were not able to categorize HT
more ﬁnely than ET vs. EPT; and thus cannot clarify if dif-
ferent formulations of ET or EPT have differential effects on
CRC risk. Finally, given the complex risk and beneﬁt proﬁle
of HT regarding other health outcomes, the current study is
meant to investigate the relationship between speciﬁc HT
and CRC in order to better understand this disease, rather
than to provide evidence for HT as CRC prevention.
Conclusions
There is consistent evidence to support an association
between EPT and CRC risk reduction. The literature for the
association between ET and CRC risk is heterogeneous, but
our analysis suggests that current use of ET may be associ-
ated with a decreased risk. Further studies that explore the
underlying biologic mechanisms for the effect of HT on CRC
are needed before a deﬁnitive causal relationship between ex-
posure and outcome can be drawn.
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